title: Cetuximab-induced cutaneous toxicity.
abstract: BACKGROUND
  Epidermal growth factor receptor inhibitors are recently utilized by oncologists in advanced cases of certain malignancies. However, these agents are associated with numerous cutaneous adverse reactions.
  
  
  OBJECTIVE
  To systematically review the cutaneous toxicity of cetuximab-treated patients.
  
  
  METHODS
  An analysis of a series of 24 patients (20 men and 4 women) treated with cetuximab (12 patients with head and neck cancer and 12 patients with colorectal cancer) was performed with respect to relevant clinical characteristics.
  
  
  RESULTS
  A total of 22 patients (91.7%) developed pustular or maculopapular follicular eruption, often referred to as acneiform rash. One patient (4.2%) developed paronychia in the course of cetuximab therapy. All patients with head and neck cancer had a combination treatment with radiotherapy and experienced radiation dermatitis accompanied by skin xerosis. Anaphylactic reaction was observed in three patients (12.5%).
  
  
  CONCLUSIONS
  The most frequent cutaneous side effect reported in this series was acneiform eruption. The authors observed that all women with acneiform rash had only limited facial involvement, whereas all but one man experienced more widespread lesions of the face, the back and the chest. We found no association between the extent and severity of cutaneous eruptions (grade 1 vs. grade 2) and patients' response to therapy.
authors.affiliation: Department of Dermatology, T Bata's Regional Hospital, Zlin, Czech Republic. tomkovah@hotmail.com
authors.forename: H
authors.initials: H
authors.lastname: Tomková
authors.forename: M
authors.initials: M
authors.lastname: Kohoutek
authors.forename: M
authors.initials: M
authors.lastname: Zábojníková
authors.forename: M
authors.initials: M
authors.lastname: Pospísková
authors.forename: L
authors.initials: L
authors.lastname: Ostrízková
authors.forename: M
authors.initials: M
authors.lastname: Gharibyar
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000453:epidemiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab